WuXi AppTec Reports 9M Revenue of RMB 45.5B, Raises Full-Year Guidance to RMB 61.0-61.9B
nashnova research
WuXi AppTec (药明康德) reported RMB 45.54 billion in revenue for the first nine months, up 38.6% year-on-year, with continuing operations growing 46.3%; the company raised its full-year revenue guidance to RMB 61.0-61.9 billion, signaling stronger confidence in its core CXO business.
How much did WuXi earn in the first nine months?
Nine-month revenue reached RMB 45.54 billion, up 38.6% year-on-year.
Revenue from continuing operations — the core business after stripping out non-core disposals — grew 46.3%, nearly 8 percentage points faster than the headline figure.
This means → the headline growth is already strong, but the core business is outpacing it — growth is driven by the real operating engine, not one-off items.
What do the profit numbers show?
Net profit attributable to shareholders came in at RMB 19.161 billion, versus RMB 11.802 billion a year earlier — an increase of over 62%.
Adjusted net profit — stripping out one-off and non-cash items — was RMB 18.380 billion, close to the reported figure.
In plain terms = profit growth far outstripped revenue growth, which means WuXi is not just winning more orders — it is earning more on each one. Operating leverage is kicking in.
Why raise full-year guidance?
The company lifted its full-year revenue guidance from RMB 58.5-60.5 billion to RMB 61.0-61.9 billion, an increase of roughly 4%.
The continuing-operations growth target was raised from 35%-39% to 40%-42%.
This means → the upgrade is not just a backward-looking confirmation of a strong nine months — it implies fourth-quarter revenue expectations are also moving up, and management has visibility on its order pipeline.
What does this mean for investors?
A ~4% guidance raise signals higher earnings certainty for the full year — the risk of a "strong start, weak finish" is shrinking.
Locking continuing-operations growth above 40% reflects accelerating demand in core CXO — contract research and manufacturing for pharma — not merely a low-base effect.
In plain terms = the company is telling the market: the pace will hold through year-end, not just through September.
市场有风险，内容仅供研究参考，不构成投资建议。